Axillary node interventions in breast cancer: A systematic review

JAMA

Volumn 310, Issue 13, 2013, Pages 1385-1394

  Rao, Roshni ^a   Euhus, David ^a   Mayo, Helen G ^b   Balch, Charles ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARM PAIN; AXILLARY LYMPH NODE; BREAST CANCER; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHEDEMA; MEDICAL DECISION MAKING; MORBIDITY; OUTCOME ASSESSMENT; PARESTHESIA; PARTIAL MASTECTOMY; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SENTINEL LYMPH NODE BIOPSY; SYSTEMATIC REVIEW;

EID: 84884970969     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.277804     Document Type: Review

References (74)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
2. Elkin EB, Hudis C, Begg CB, Schrag D. The effect of changes in tumor size on breast carcinoma survival in the US: 1975-1999. Cancer. 2005;104(6):1149- 1157. (Pubitemid 41278949)
3. Fenton JJ, Abraham L, Taplin SH, et al Breast Cancer Surveillance Consortium. Effectiveness of computer-aided detection in community mammography practice. J Natl Cancer Inst. 2011;103(15):1152-1161.
4. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233-1241. (Pubitemid 35176242)
5. Veronesi U, Salvadori B, Luini A, et al. Conservative treatment of early breast cancer: long-term results of 1232 cases treated with quadrantectomy, axillary dissection, and radiotherapy. Ann Surg. 1990;211(3):250-259. (Pubitemid 20105976)
6. Cotlar AM, Dubose JJ, Rose DM. History of surgery for breast cancer: radical to the sublime. Curr Surg. 2003;60(3):329-337. (Pubitemid 36512106)
7. Halsted WS. The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June, 1889, to January, 1894. Ann Surg. 1894;20(5):497-555.
8. Carlson RW, Anderson BO, Bensinger W, et al National Comprehensive Cancer Network. NCCN practice guidelines for breast cancer. Oncology (Williston Park). 2000;14(11A):33-49.
9. Fleissig A, Fallowfield LJ, Langridge CI, et al. Post-operative arm morbidity and quality of life: results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat. 2006;95(3):279-293.
10. Bevers TB, Anderson BO, Bonaccio E, et al National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw. 2009;7(10):1060-1096.
11. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
12. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220(3):391-398.
13. Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927-933.
14. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349(6):546-553. (Pubitemid 36951366)
15. Krag DN, Anderson SJ, Julian TB, et al National Surgical Adjuvant Breast and Bowel Project. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8(10):881-888. (Pubitemid 47488052)
16. Krag DN, Ashikaga T, Harlow SP, et al National Surgical Adjuvant Breast and Bowel Project. Surgeon training, protocol compliance, and technical outcomes from breast cancer sentinel lymph node randomized trial. J Natl Cancer Inst. 2009;101(19):1356-1362.
17. National Comprehensive Cancer Network. Update: NCCN practice guidelines for the treatment of breast cancer. Oncology (Williston Park). 1999;13(5A):41-66.
18. Carlson RW, Allred DC, Anderson BO, et al NCCN Breast Cancer Clinical Practice Guidelines Panel. Breast cancer. clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2009;7(2):122-192.
19. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569-575.
20. Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252(3):426-432.
21. Gainer SM, Hunt KK, Beitsch P, Caudle AS, Mittendorf EA, Lucci A. Changing behavior in clinical practice in response to the ACOSOG Z0011 trial: a survey of the American Society of Breast Surgeons. Ann Surg Oncol. 2012;19(10):3152-3158.
22. Jacobs AK, Kushner FG, Ettinger SM, et al. ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(2):213-265.
23. Yates L, Kirby A, Crichton S, et al. Risk factors for regional nodal relapse in breast cancer patients with 1 to 3 positive axillary nodes. Int J Radiat Oncol Biol Phys. 2012;82(5):2093-2103.
24. Langer I, Marti WR, Guller U, et al. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy. Ann Surg. 2005;241(1):152-158. (Pubitemid 40041004)
25. Rivadeneira DE, Simmons RM, Christos PJ, Hanna K, Daly JM, Osborne MP. Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients. J Am Coll Surg. 2000;191(1):1-6.
26. Barth A, Craig PH, Silverstein MJ. Predictors of axillary lymph node metastases in patients with T1 breast carcinoma. Cancer. 1997;79(10):1918-1922. (Pubitemid 27200375)
27. Barthelmes L, Goyal A, Newcombe RG, McNeill F, Mansel RE; NEW START and ALMANAC Study Groups. Adverse reactions to patent blue V dye-the NEW START and ALMANAC experience. Eur J Surg Oncol. 2010;36(4):399-403.
28. Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347(8):567-575.
29. Greco M, Agresti R, Cascinelli N, et al. Breast cancer patients treated without axillary surgery: clinical implications and biologic analysis. Ann Surg. 2000;232(1):1-7. (Pubitemid 30456543)
30. Martelli G, Miceli R, Costa A, et al. Elderly breast cancer patients treated by conservative surgery alone plus adjuvant tamoxifen: 15-year results of a prospective study. Cancer. 2008;112(3):481-488. (Pubitemid 351186188)
31. Hughes KS, Schnaper LA, Berry D, et al; Cancer and Leukemia Group B; Radiation Therapy Oncology Group; Eastern Cooperative Oncology Group. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351(10):971-977. (Pubitemid 39166260)
32. Rudenstam CM, Zahrieh D, Forbes JF, et al International Breast Cancer Study Group. Randomized trial comparing axillary clearance vs no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. J Clin Oncol. 2006;24(3):337-344. (Pubitemid 46630451)
33. Harris JR, Osteen RT. Patients with early breast cancer benefit from effective axillary treatment. Breast Cancer Res Treat. 1985;5(1):17-21. (Pubitemid 15163213)
34. Martelli G, Boracchi P, De Palo M, et al. A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer: results after 5 years of follow-up. Ann Surg. 2005;242(1):1-6. (Pubitemid 40917960)
35. Rao R, Lilley L, Andrews V, Radford L, Ulissey M. Axillary staging by percutaneous biopsy: sensitivity of fine-needle aspiration vs core needle biopsy. Ann Surg Oncol. 2009;16(5):1170-1175.
36. Krishnamurthy S. Current applications and future prospects of fine-needle aspiration biopsy of locoregional lymph nodes in the management of breast cancer. Cancer. 2009;117(6):451-462.
37. Hoebers FJ, Borger JH, Hart AA, Peterse JL, Th EJ, Lebesque JV. Primary axillary radiotherapy as axillary treatment in breast-conserving therapy for patients with breast carcinoma and clinically negative axillary lymph nodes. Cancer. 2000;88(7):1633-1642. (Pubitemid 30183149)
38. Louis-Sylvestre C, Clough K, Asselain B, et al. Axillary treatment in conservative management of operable breast cancer: dissection or radiotherapy? results of a randomized study with 15 years of follow-up. J Clin Oncol. 2004;22(1):97-101. (Pubitemid 41095119)
39. Halverson KJ, Taylor ME, Perez CA, et al. Regional nodal management and patterns of failure following conservative surgery and radiation therapy for stage I and II breast cancer. Int J Radiat Oncol Biol Phys. 1993;26(4):593-599. (Pubitemid 23220155)
40. Wang Z, Wu LC, Chen JQ. Sentinel lymph node biopsy compared with axillary lymph node dissection in early breast cancer: a meta-analysis. Breast Cancer Res Treat. 2011;129(3):675-689.
41. Straver ME, Meijnen P, van Tienhoven G, et al. Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial. Ann Surg Oncol. 2010;17(7):1854-1861.
42. Gill G; SNAC Trial Group of the Royal Australasian College of Surgeons and NHMRC Clinical Trials Centre. Sentinel-lymph-node-based management or routine axillary clearance? one-year outcomes of sentinel node biopsy vs axillary clearance (SNAC): a randomized controlled surgical trial. Ann Surg Oncol. 2009;16(2):266-275.
43. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy vs standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006;98(9):599-609. (Pubitemid 43904843)
44. Zavagno G, De Salvo GL, Scalco G, et al GIVOM Trialists. A randomized clinical trial on sentinel lymph node biopsy vs axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg. 2008;247(2):207-213. (Pubitemid 351156760)
45. Johansen H, Kaae S, Jensen MB, Mouridsen HT. Extended radical mastectomy vs simple mastectomy followed by radiotherapy in primary breast cancer: a 50-year follow-up to the Copenhagen Breast Cancer randomised study. Acta Oncol. 2008;47(4):633-638. (Pubitemid 351878446)
46. Johansen H, Kaae S, Schiødt T. Simple mastectomy with postoperative irradiation vs extended radical mastectomy in breast cancer: a 25-year follow-up of a randomized trial. Acta Oncol. 1990;29(6):709-715. (Pubitemid 20354518)
47. Veronesi U, Orecchia R, Zurrida S, et al. Avoiding axillary dissection in breast cancer surgery: a randomized trial to assess the role of axillary radiotherapy. Ann Oncol. 2005;16(3):383-388. (Pubitemid 40458313)
48. Veronesi U, Viale G, Paganelli G, et al. Sentinel lymph node biopsy in breast cancer: 10-year results of a randomized controlled study. Ann Surg. 2010;251(4):595-600.
49. Canavese G, Catturich A, Vecchio C, et al. Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: results of randomized trial. Ann Oncol. 2009;20(6):1001-1007.
50. Gill PG. Sentinel lymph node biopsy vs axillary clearance in operable breast cancer: the RACS SNAC trial, a multicenter randomized trial of the Royal Australian College of Surgeons (RACS) Section of Breast Surgery, in collaboration with the National Health and Medical Research Council Clinical Trials Center. Ann Surg Oncol. 2004;11(3)(suppl):216S-221S.
51. Cox CE, Salud CJ, Cantor A, et al. Learning curves for breast cancer sentinel lymph node mapping based on surgical volume analysis. J Am Coll Surg. 2001;193(6):593-600. (Pubitemid 33111529)
52. Galimberti V, Cole BF, Zurrida S, et al International Breast Cancer Study Group Trial 23-01 Investigators. Axillary dissection vs no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14(4):297-305.
53. Lucci A, McCall LM, Beitsch PD, et al American College of Surgeons Oncology Group. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007;25(24):3657-3663. (Pubitemid 47372604)
54. Del Bianco P, Zavagno G, Burelli P, et al GIVOM. Morbidity comparison of sentinel lymph node biopsy vs conventional axillary lymph node dissection for breast cancer patients: results of the Sentinella-GIVOM Italian randomised clinical trial. Eur J Surg Oncol. 2008;34(5):508-513. (Pubitemid 351514885)
55. Helyer LK, Varnic M, Le LW, Leong W, McCready D. Obesity is a risk factor for developing postoperative lymphedema in breast cancer patients. Breast J. 2010;16(1):48-54.
56. Shah C, Wilkinson JB, Baschnagel A, et al. Factors associated with the development of breast cancer-related lymphedema after whole-breast irradiation. Int J Radiat Oncol Biol Phys. 2012;83(4):1095-1100.
57. Van Zee KJ, Manasseh DM, Bevilacqua JL, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003;10(10):1140-1151. (Pubitemid 40486808)
58. Kohrt HE, Olshen RA, Bermas HR, et al Bay Area SLN Study. New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer. 2008;8:66.
59. Mittendorf EA, Hunt KK, Boughey JC, et al. Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. Ann Surg. 2012;255(1):109-115.
60. van la Parra RF, Ernst MF, Bevilacqua JL, et al. Validation of a nomogram to predict the risk of nonsentinel lymph node metastases in breast cancer patients with a positive sentinel node biopsy: validation of the MSKCC breast nomogram. Ann Surg Oncol. 2009;16(5):1128-1135.
61. Alran S, De Rycke Y, Fourchotte V, et al Institut Curie Breast Cancer Study Group. Validation and limitations of use of a breast cancer nomogram predicting the likelihood of non-sentinel node involvement after positive sentinel node biopsy. Ann Surg Oncol. 2007;14(8):2195-2201. (Pubitemid 47174905)
62. Gur AS, Unal B, Johnson R, et al. Predictive probability of four different breast cancer nomograms for nonsentinel axillary lymph node metastasis in positive sentinel node biopsy. J Am Coll Surg. 2009;208(2):229-235.
63. Memorial Sloan-Kettering Cancer Center. Breast cancer prediction tools. 2012. http://www.mskcc.org/cancer-care/adult/breast/prediction-tools. Accessed February 20, 2012.
64. Andersson Y, de Boniface J, Jönsson PE, et al Swedish Breast Cancer Group; Swedish Society of Breast Surgeons. Axillary recurrence rate 5 years after negative sentinel node biopsy for breast cancer. Br J Surg. 2012;99(2):226-231.
65. Goodman MD, McIntyre B, Shaughnessy EA, Lowy AM, Ahmad SA. Forequarter amputation for recurrent breast cancer: a case report and review of the literature. J Surg Oncol. 2005;92(2):134-141. (Pubitemid 41572156)
66. Fredriksson I, Liljegren G, Arnesson LG, et al. Consequences of axillary recurrence after conservative breast surgery. Br J Surg. 2002;89(7):902-908. (Pubitemid 34779576)
67. Grills IS, Kestin LL, Goldstein N, et al. Risk factors for regional nodal failure after breast-conserving therapy: regional nodal irradiation reduces rate of axillary failure in patients with 4 or more positive lymph nodes. Int J Radiat Oncol Biol Phys. 2003;56(3):658-670. (Pubitemid 36677358)
68. Galper S, Recht A, Silver B, et al. Factors associated with regional nodal failure in patients with early stage breast cancer with 0-3 positive axillary nodes following tangential irradiation alone. Int J Radiat Oncol Biol Phys. 1999;45(5):1157-1166.
69. Albain KS, Paik S, van't Veer L. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast. 2009;18(suppl 3):S141-S145.
70. Kim C, Paik S. Gene-expression-based prognostic assays for breast cancer. Nat Rev Clin Oncol. 2010;7(6):340-347.
71. Mamounas EP, Tang G, Fisher B, et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol. 2010;28(10):1677-1683.
72. Harvell DM, Spoelstra NS, Singh M, et al. Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance. Breast Cancer Res Treat. 2008;112(3):475-488.
73. Korkola JE, DeVries S, Fridlyand J, et al. Differentiation of lobular vs ductal breast carcinomas by expression microarray analysis. Cancer Res. 2003;63(21):7167-7175. (Pubitemid 37413454)
74. Albain KS, Barlow WE, Shak S, et al Breast Cancer Intergroup of North America. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55-65.